Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase EARLY_PHASE1 1Phase 1/2 1

Status

Completed 3Terminated 1Suspended 1Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Carcinoma, Non-Small-Cell Lung 123Breast Neoplasms 103Neoplasms 100Leukemia, Myeloid, Acute 88Melanoma 86Multiple Myeloma 81Neoplasm Metastasis 80Recurrence 68Ovarian Neoplasms 65Prostatic Neoplasms 59Lymphoma 59Colorectal Neoplasms 58Lymphoma, Non-Hodgkin 55Leukemia 55Pancreatic Neoplasms 50Lung Neoplasms 48Myelodysplastic Syndromes 42Leukemia, Lymphocytic, Chronic, B-Cell 42Carcinoma, Renal Cell 39Squamous Cell Carcinoma of Head and Neck 38Precursor Cell Lymphoblastic Leukemia-Lymphoma 38Glioblastoma 35Lymphoma, Large B-Cell, Diffuse 34Carcinoma, Hepatocellular 33Triple Negative Breast Neoplasms 32Stomach Neoplasms 29Small Cell Lung Carcinoma 27Lymphoma, Follicular 27Brain Neoplasms 26Lymphoma, Mantle-Cell 25

Interventions

ruxolitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Terminated × Leukemia-Lymphoma, Adult T-Cell × Clear all
NCT01712659 2023-01-10

Ruxolitinib for Adult T-Cell Leukemia

National Institutes of Health Clinical Center (CC)

Phase 1/2 Terminated
19 enrolled 17 charts
LymphoidOther hematologic neoplasm

Leukemia, T-Cell, Leukemia-Lymphoma, Adult T-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡